Therapeutic Hydrocortisone

Phase 3Small molecule

Therapeutic Hydrocortisone is one of 351 small molecule programs targeting Lymphoblastic Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

350

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lymphoblastic LymphomaActive, not recruiting

Anaplastic Large Cell LymphomaActive, not recruiting

NeurotoxicityActive, not recruiting

LymphomaActive, not recruiting

HistiocytosisActive, not recruiting

LeukemiaActive, not recruiting

NeuroblastomaActive, not recruiting

Precursor B-Cell Acute Lymphoblastic LeukemiaActive, not recruiting

Bone Marrow TransplantationActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

Lymphoblastic LymphomaPhase 2/Phase 3

Active, not recruiting

Anaplastic Large Cell LymphomaPhase 1/Phase 2

Active, not recruiting

NeurotoxicityPhase 2

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

HistiocytosisPhase 3

Active, not recruiting

LeukemiaPhase 2

Active, not recruiting

NeuroblastomaPhase 3

Active, not recruiting

Precursor B-Cell Acute Lymphoblastic LeukemiaPhase 2

Active, not recruiting

Bone Marrow TransplantationPhase 3

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

Showing 10 of 17 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Therapeutic Hydrocortisone

EEastern Cooperative Oncology Group

Phase 3

4 2

Norvir

AbbVie

Preclinical

1 3

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 4

Nuvigil

NNuvo Research GmbH

Preclinical

1 5

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—6

Decadron

QQuince Therapeutics S.p.A.

Systemic Therapy

1 8

PEG-Intron

Merck & Co.

Preclinical

1 9

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

3 10

VP-16

FFundamenta Therapeutics, Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

B-Cell Acute Lymphoblastic Leukemia

NCT02101853

Q3 2027

Phase 3Active, not recruiting

Acute Lymphoblastic Leukemia

NCT03007147

Q4 2027

Phase 2Recruiting

Hematopoietic and Lymphatic System Neoplasm

NCT06895473

Q4 2028

Phase 2Recruiting

Acute Leukemia of Ambiguous Lineage

NCT06317662

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukemia17 trials

Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma

Completed·CChildren's Oncology Group·Phase 3·NCT01230983·573 enrolled

Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00002704·156 enrolled

Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)

Completed·CChildren's Oncology Group·Phase 1/2·NCT00098839·134 enrolled

Show 14 more trials

Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·—·Phase 2·NCT00618501·50 enrolled

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00002744·1,970 enrolled

Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 2·NCT00002756·221 enrolled

Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00002816·120 enrolled

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT03007147·475 enrolled

Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00873093·148 enrolled

Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic Leukemia

Withdrawn·NNational Institutes of Health Clinical Center (CC)·Phase 3·NCT00019409

05-001: Treatment of Acute Lymphoblastic Leukemia in Children

Completed·—·Phase 3·NCT00400946·800 enrolled

Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 2·NCT00002785

Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00557193·218 enrolled

Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00003728·1,500 enrolled

Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·N/A·NCT00049569·126 enrolled

Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes

Completed·CChildren's Oncology Group·N/A·NCT00096135·168 enrolled

Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002700·392 enrolled

Prostate Cancer9 trials

Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00002855·306 enrolled

Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy

Completed·UUniversity of California, San Francisco·Phase 2·NCT00309894·49 enrolled

Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Completed·—·Phase 2·NCT00460031·34 enrolled

Show 6 more trials

Ketoconazole, Dexamethasone, and Hydrocortisone in Treating Patients With Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy

Withdrawn·RRoswell Park Cancer Institute·N/A·NCT00559481

Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00027859

Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer

Terminated·RRoswell Park Cancer Institute·Phase 1/2·NCT00536991·51 enrolled

Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00002760·260 enrolled

A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00006371·2 enrolled

Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00002881

Leukemia4 trials

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00002494·134 enrolled

Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002471

High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia

Completed·WWake Forest University Health Sciences·Phase 2·NCT00002865·25 enrolled

Show 1 more trial

Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00005802

Lymphoma4 trials

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Unknown status·NNorthwestern University·Phase 1/2·NCT02481310·38 enrolled

TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma

Completed·CChildren's Oncology Group·Phase 3·NCT00002757·1,148 enrolled

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma

Completed·SSwiss Cancer Institute·Phase 3·NCT00003215·400 enrolled

Show 1 more trial

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

Completed·AAIDS Malignancy Consortium·Phase 2·NCT00392834·34 enrolled

Bone Marrow Transplantation3 trials

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia

Completed·MMedical Research Council·Phase 3·NCT00003436·2,000 enrolled

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00002552·40 enrolled

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00002798·880 enrolled

18 more indications

Anaplastic Large Cell Lymphoma2 trials

Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma (ALCL 99)

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT00006455·885 enrolled

Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00354107·5 enrolled

Myelodysplastic Syndrome2 trials

Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed·CChildren's Oncology Group·Phase 2·NCT00002805·115 enrolled

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT03813147·12 enrolled

Advanced Cancer1 trial

Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab

Completed·—·Phase 2·NCT01867294·19 enrolled

Neuroblastoma1 trial

Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma

Completed·CChildren's Oncology Group·Phase 3·NCT00033293·53 enrolled

Stem Cell Transplant1 trial

Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer

Completed·IInstitut Paoli-Calmettes·Phase 2·NCT00806767·82 enrolled

Bone Marrow Transplant1 trial

Bone Marrow Transplant Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic Cancer

Completed·TTemple University·Phase 2·NCT00002809·10 enrolled

Precursor B-Cell Acute Lymphoblastic Leukemia1 trial

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT01700946·80 enrolled

B-cell acute lymphoblastic leukemia1 trial

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02101853·669 enrolled

Newly Diagnosed1 trial

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Recruiting·CChildren's Oncology Group·Phase 3·NCT04293562·1,186 enrolled

Hematologic Cancer1 trial

506U78 in Treating Patients With Refractory Hematologic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00002970·148 enrolled

Histiocytosis1 trial

Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 3·NCT00334672·288 enrolled

Myeloproliferative Disorder1 trial

Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome

Completed·CChildren's Oncology Group·Phase 3·NCT00003593·254 enrolled

Lymphoblastic Lymphoma1 trial

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Not yet recruiting·CChildren's Oncology Group·Phase 2/3·NCT07072585·1,708 enrolled

Radiation Therapy1 trial

Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT

Completed·—·Phase 2·NCT00084838·25 enrolled

Stage III1 trial

S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery

Terminated·SSWOG Cancer Research Network·Phase 2·NCT00002921·13 enrolled

Acute Leukemia1 trial

Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia

Unknown status·DDutch Childhood Oncology Group·N/A·NCT00550992·445 enrolled

Acute Leukemia of Ambiguous Lineage1 trial

A Phase 2 Study of Blinatumomab in Combination With Chemotherapy for Infants With Newly Diagnosed Acute Lymphoblastic Leukemia With Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06317662·153 enrolled

Hematopoietic and Lymphatic System Neoplasm1 trial

A Phase 2 Study of Prophylactic IT Chemotherapy to Prevent High-Grade Chimeric Antigen Receptor (CAR) T-Cell-Associated Neurotoxicity Syndrome

Recruiting·OOHSU Knight Cancer Institute·Phase 2·NCT06895473·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 57 trial records for Therapeutic Hydrocortisone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Therapeutic Hydrocortisone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Therapeutic Hydrocortisone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eastern Cooperative Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEastern Cooperative Oncology Group

Therapeutic Hydrocortisone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q3 2027

Q4 2027

Q4 2028

Trials by Indication[1]

Acute Lymphoblastic Leukemia17 trials

Prostate Cancer9 trials

Leukemia4 trials

Lymphoma4 trials

Bone Marrow Transplantation3 trials

Anaplastic Large Cell Lymphoma2 trials

Myelodysplastic Syndrome2 trials

Advanced Cancer1 trial

Neuroblastoma1 trial

Stem Cell Transplant1 trial

Bone Marrow Transplant1 trial

Precursor B-Cell Acute Lymphoblastic Leukemia1 trial

B-cell acute lymphoblastic leukemia1 trial

Newly Diagnosed1 trial

Hematologic Cancer1 trial

Histiocytosis1 trial

Myeloproliferative Disorder1 trial

Lymphoblastic Lymphoma1 trial

Radiation Therapy1 trial

Stage III1 trial

Acute Leukemia1 trial

Acute Leukemia of Ambiguous Lineage1 trial

Hematopoietic and Lymphatic System Neoplasm1 trial

References

Drug Info

Quick Facts

Related News